Biogen (BIIB) 10-K Summary — Year Ended Dec 31, 2024
The filing provides limited business description but details a major acquisition in immunology. Revenue declined, while net income and operating cash flow were reported.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
The filing provides limited business description but details a major acquisition in immunology. Revenue declined, while net income and operating cash flow were reported.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$9.7B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$1.6B
Net income reported for the year.
Operating cash flow
$2.9B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11B | n/a |
| Dec 31, 2022 | $10.2B | -7.4% |
| Dec 31, 2023 | $9.8B | -3.3% |
| Dec 31, 2024 | $9.7B | -1.6% |
Business overview
The filing's business overview section lacks a description of the company's operations. However, the company's acquisition of a clinical-stage biotechnology firm focused on immune-mediated diseases indicates its involvement in developing targeted therapies for severe immune conditions.
Financial performance
Revenue decreased compared to the prior year. Net income and operating cash flow were reported for the year.
Material risks
The filing does not provide specific risk factor descriptions. Therefore, no material risks can be identified from the supplied context.
Liquidity and capital
Cash and cash equivalents increased significantly, driven by operating cash flow and proceeds from the sale of a rare pediatric disease priority review voucher and an equity interest in a partner. The company used available cash to fund the acquisition of a biotechnology firm.
What to watch
In the next filing, readers should monitor the clinical development and regulatory progress of felzartamab, the lead asset acquired from HI-Bio.